ELCC 2016: Targeting PD-1 and PD-L1 for lung cancer therapy

ELCC 2016: Targeting PD-1 and PD-L1 for lung cancer therapy

User Photo
VJOncology

4 years
410 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, explains the development of antibodies targeting the programmed death ligand 1 (PD-L1) and its receptor, programmed death 1 (PD-1) for the treatment of patients with non-small cell lung cancer (NSCLC), including clinical trials evaluating the integration of PD-1/PD-L1blocking antibodies with existing standard-of-care approaches.
Up Next Autoplay